- Trial phase
- Approved
- Time to market
- Already approved and commercially marketed (FDA-approved since 2014)
- Why 4/10
- No hard dated catalyst for RUCONEST itself, it is already FDA-approved and commercially marketed with no pending PDUFA or pivotal readout. The impactScore is 4 because this is an approved drug with no pending binary; the company's next catalysts (Q3 earnings Oct 27, leniolisib CVID data Nov 2026) are for other pipeline assets, not RUCONEST.
RUCONEST is a mature, approved product with no pending binary catalyst for this specific drug. The next company-wide catalysts are the full Q3 2026 earnings on October 27 and the leniolisib CVID Phase II topline in November 2026, but those are for Joenja, not RUCONEST. Watch RUCONEST's revenue trajectory (Q3 showed +14% growth) and whether the inventory-driven rebound is sustainable against competitive pressure from newer HAE therapies.
Price Chart
Executive Summary
RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for treating acute attacks of hereditary angioedema (HAE). Developed and commercialized by Pharming Group N.V. (Nasdaq: PHAR), RUCONEST was FDA-approved in 2014 and remains the company's largest revenue driver, generating ~$93.8M in Q3 2026 (preliminary, +14% YoY). However, RUCONEST revenue has been declining on a YoY basis through H1 2026 as the HAE market faces competition from newer prophylactic therapies. Pharming is also growing its second product, Joenja (leniolisib), which is growing rapidly. Analyst consensus is Strong Buy with a mean price target of $34.35 (234.8% upside from ~$11.20), but the stock is down ~48% from its 52-week high of $21.34.
How It Works
RUCONEST is a recombinant (genetically engineered) version of human C1 esterase inhibitor, a protein that blocks the inflammatory cascade that causes swelling attacks in hereditary angioedema (HAE). It replaces the missing or dysfunctional C1 inhibitor that HAE patients lack. It is given intravenously to treat acute HAE attacks.
Trial Status
RUCONEST is FDA-approved and commercially marketed for HAE. A separate Phase 2 investigator-sponsored trial (NCT05145283) evaluating conestat alfa for preventing acute ischemic events after transcatheter aortic valve implantation (TAVI) completed enrollment of 141 patients in January 2026, with results not yet reported.
The Two-Sided Case
Upcoming Catalysts
- No pending regulatory or pivotal readout for RUCONEST itself. The company's next catalysts are full Q3 2026 results (October 27, 2026) and leniolisib Phase II CVID topline data (November 2026), both for other pipeline assets.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Pharming Group N.V. 6-K PHAR ·Originating report